CytomX Therapeutics, Inc. financial data

Symbol
CTMX on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 16 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 307% % 179%
Debt-to-equity 66% %
Return On Equity -20% % 87%
Return On Assets -12% % -156%
Operating Margin -29% % -262%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 170,186,742 shares
Common Stock, Shares, Outstanding 170,186,365 shares 112%
Entity Public Float $372,300,000 USD 294%
Common Stock, Value, Issued $2,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 137,935,873 shares 63%
Weighted Average Number of Shares Outstanding, Diluted 137,935,873 shares 63%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $76,201,000 USD -45%
Revenue from Contract with Customer, Excluding Assessed Tax $76,201,000 USD -45%
Research and Development Expense $68,728,000 USD -18%
General and Administrative Expense $29,837,000 USD 0.37%
Operating Income (Loss) $22,364,000 USD -189%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $17,130,000 USD -153%
Income Tax Expense (Benefit) $238,000 USD 6.2%
Net Income (Loss) Attributable to Parent $17,368,000 USD -154%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,667,000 USD -67%
Cash, Cash Equivalents, and Short-term Investments $79,900,000 USD -48%
Accounts Receivable, after Allowance for Credit Loss, Current $2,013,000 USD -35%
Assets, Current $143,921,000 USD 34%
Property, Plant and Equipment, Net $1,304,000 USD -47%
Operating Lease, Right-of-Use Asset $3,396,000 USD -58%
Goodwill $949,000 USD 0%
Other Assets, Noncurrent $31,000 USD -53%
Assets $151,566,000 USD 26%
Accounts Payable, Current $1,301,000 USD 20%
Employee-related Liabilities, Current $8,209,000 USD 218%
Accrued Liabilities, Current $14,197,000 USD 15%
Contract with Customer, Liability, Current $26,877,000 USD -60%
Liabilities, Current $46,615,000 USD -46%
Contract with Customer, Liability, Noncurrent $1,590,000 USD -94%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $4,353,000 USD 5.8%
Liabilities $52,558,000 USD -57%
Accumulated Other Comprehensive Income (Loss), Net of Tax $111,000 USD 311%
Retained Earnings (Accumulated Deficit) $711,949,000 USD -2.9%
Stockholders' Equity Attributable to Parent $99,008,000 USD
Liabilities and Equity $151,566,000 USD 26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,043,000 USD 19%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $30,596,000 USD -32%
Common Stock, Shares Authorized 300,000,000 shares 100%
Common Stock, Shares, Issued 170,186,365 shares 112%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $187,342,000 USD 16%
Deferred Tax Assets, Gross $188,274,000 USD 15%
Operating Lease, Liability $9,385,000 USD -33%
Payments to Acquire Property, Plant, and Equipment $119,000 USD 3.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $17,284,000 USD -154%
Lessee, Operating Lease, Liability, to be Paid $10,116,000 USD -36%
Property, Plant and Equipment, Gross $18,224,000 USD -2.5%
Operating Lease, Liability, Current $4,240,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,387,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,729,000 USD 2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.0825 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $731,000 USD -57%
Deferred Tax Assets, Operating Loss Carryforwards $84,916,000 USD 36%
Unrecognized Tax Benefits $20,207,000 USD 1.1%
Additional Paid in Capital $810,844,000 USD 17%
Amortization of Intangible Assets $36,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $932,000 USD -56%